Stribild, as a novel option of integrase inhibitor based single tablet regimen for the treatment of HIV infection

Single tablet regimens (STR) have recently been expanded with the first integrase inhibitor based regimen containing elvitegravir, cobicistat, tenofovir and emtricitabine. This therapeutic option allows for the once daily treatment and has been proven to be a safe and effective therapeutic option for both antiretroviral treatment naive and experienced patients. It is characterized by rapid decrease of plasma viremia after introduction, high efficacy regardless the baseline HIV-1 viral load as well as favorable safety profile, including lipid parameters and infrequent CNS-related adverse events. As STRs eliminate the possibility of selective adherence, once daily dosing allows for improved compliance among antiretroviral patients. It may be introduced in patients with no drug resistance to the components of the regimen with eGFR > 90 ml/min. In this review we present basic characteristics of the combination.